Emerging Limbrel Litigation (flavocoxid)
(MASS TORT NEXUS) Limbrel (flavocoxid) is marketed as an FDA-regulated medical food for the clinical dietary management of osteoarthritis (OA) to be used under physician supervision. Flavocoxid is composed mixture of baicalin and catechin and represents a non-targeted anti-inflammatory which works differently than non-steroidal anti-inflammatory drugs (NSAIDs)
Primus Pharmaceuticals voluntarily ceased its promotion and distribution of Limbrel on December 21, 2017, and issued a recall of Limbrel after a request from the FDA, see Limbrel-(Osteoarthritis-Drug)-FDA-Recall-Investigation.
Adverse events now associated with Limbrel include potential liver damage and hypersensitivity pneumonitis, according to records obtained from the FDA.
Learn More About the Emerging Limbrel Litigation, see Limbrel Emerging Litigation Briefcase by Mass Tort Nexus
The emerging Limbrel Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May CouRse, contact Jenny Levine at email@example.com or call (954) 520-4494.
For information on the class and to enroll, use this link: Enroll Here To Attend “Four Days to Mass Tort Success”:
Course attendees will receive the benefit of a step by step analysis of the emerging Limbrel Litigation, using these primary metrics:
Some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course have provide endorsements below>
The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts is considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively. Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.